Koenig, Scott, MD

Add to Favorites

Physicians & Surgeons, Physicians & Surgeons, Allergy & Immunology, Physicians & Surgeons, Dermatology

Be the first to review!

Add Hours

(301) 251-5172Visit WebsiteMap & Directions1500 E Gude Dr # DRockville, MD 20850 Write a Review

Accepted Insurance

Koenig, Scott, MD has not yet specified accepted insurance plans.

Specialties

Additional Specialties: Allergy & Immunology, Infectious Diseases

More Info

Extra Phones: Fax: (301) 251-5321
Neighborhood: East Rockville
Other Link: http://macrogenics.com
Categories: Physicians & Surgeons, Physicians & Surgeons, Allergy & Immunology, Physicians & Surgeons, Dermatology, Physicians & Surgeons, Gynecology, Physicians & Surgeons, Infectious Diseases, Physicians & Surgeons, Obstetrics And Gynecology, Physicians & Surgeons, Oncology, Skin Care

Gallery

Be the first to add a photo!

Reviews

Hi there!
Be the first to review!

Click to Rate

Details

Phone: (301) 251-5172

Address: 1500 E Gude Dr # D, Rockville, MD 20850

Website: http://macrogenics.com

People Also Viewed

View similar Physicians & Surgeons

Suggest an Edit

Koenig, Scott, MD

General Practitioners

Infectious Diseases
MacroGenics is a biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases.

Labor and Delivery
Demographic Information; Protected Classification Characteristics: Age, gender, race or ethnicity, ancestry, national origin, citizenship, sexual orientation, veteran or military status, religion or creed, marital status, physical or mental disability, sex (including gender, gender identity, gender expression, pregnancy or childbirth and related medical conditions), sexual orientation

Prostate Cancer
At ASCO in June 2022, investigators from Johns Hopkins presented a poster with encouraging clinical activity from an ongoing investigator-sponsored, single-center, single-arm, open-label Phase 2 study of enoblituzumab in patients with localized prostate cancer in the neoadjuvant setting.
Lung Cancer
Enoblituzumab was evaluated in a Phase 1 clinical study in combination with an anti-PD-1 monoclonal antibody in patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC) and urothelial cancer. Data were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2018.

Chemotherapy
® molecule) in PD-L1 negative patients as chemotherapy‐free regimens in front‐line recurrent and metastatic SCCHN. As of July 8, 2022, this study was closed for safety reasons. Please see press release.

Skin Cancer
MGC018 is currently being evaluated in a Phase 1/2 dose expansion study in patients with metastatic castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN) and melanoma. Preliminary results from the dose escalation phase of this study were presented at the 2020 American Society for Clinical Oncology (ASCO) Scientific Program. Preliminary results from the dose expansion phase of this study were presented at the 2021 ASCO Annual Meeting and the 2021 European Society for Medical Oncology (ESMO) Annual Meeting.

View All Services

Provided by